{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-000154","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.375425+00:00","generated_at":"2026-06-20T18:27:11.933268+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioCryst prelim 2022 ORLADEYO rev $251.6M (+105% YoY); FY23 guide ≥$320M; BCX10013 data positive","bullets":["Prelim 2022 ORLADEYO net rev $251.6M (+105% YoY); Q4 rev $70.7M (+53% YoY).","FY2023 ORLADEYO net rev guidance no less than $320M; company expects peak sales of $1B.","Phase1 data for BCX10013 (oral Factor D inhibitor): >97% AP suppression at 110 mg single dose, safe/well-tolerated.","Advancing BCX10013 into patient studies mid-2023 for PNH and IgAN; expanding complement platform to C2 targets."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-000154","json":"https://secwatch.observer/filing/0001171843-23-000154.json","markdown":"https://secwatch.observer/filing/0001171843-23-000154.md","text":"https://secwatch.observer/filing/0001171843-23-000154.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184323000154/0001171843-23-000154-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184323000154/f8k_010923.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:27:11.933268+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ff8b3a2568e653aad27953cded22e872fbbe3bef","claim":"BIOCRYST PHARMACEUTICALS INC reported the fourth quarter and full year ended December 31, 2022 results: revenue $70.7 million. Guidance raised.","evidence_excerpt":"for many years to come,” said Jon Stonehouse, president and chief executive officer of BioCryst. Preliminary, unaudited ORLADEYO net revenue in the fourth quarter of 2022 was $70.7 million (+53 percent y-o-y). Preliminary, unaudited ORLADEYO net revenue for full year 2022 was $251.6 million (+105 percent y-o-y). Fourth Quarter and Full Year 2022 ORLADEYO Revenue","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882796/000117184323000154/0001171843-23-000154-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Revenue","value":"$70.7 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}